Every Form 4 that Instil Bio, Inc. (TIL) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow TIL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TIL filings page.
Instil Bio director R. Kent McGaughy Jr received a stock option grant covering 6,500 shares of common stock at an exercise price of $7.93 per share. The option vests in 12 substantially equal monthly installments starting on July 11, 2026, with any unvested portion vesting in full at the next annual stockholder meeting or upon death, Disability, or a Change in Control, subject to continued service.
Instil Bio, Inc. director George Matcham received a grant of stock options covering 6,500 shares of common stock at an exercise price of $7.93 per share. The options were awarded at no purchase price and will vest in 12 substantially equal monthly installments starting on July 11, 2026, subject to his continuous service. Any unvested portion will vest in full at the next annual stockholder meeting, or upon his death, disability, or a change in control, as defined in the company’s 2021 Equity Incentive Plan. Following this grant, he holds 6,500 stock options directly.
Instil Bio director Neil W. Gibson received a stock option grant as compensation. The award covers 6,500 shares of common stock at an exercise price of $7.93 per share and expires on June 10, 2036. The option vests in 12 monthly installments starting July 11, 2026, with accelerated vesting upon the next annual stockholder meeting, death, disability, or a change in control, if he remains in continuous service.
Instil Bio, Inc. director Gwendolyn Binder received a grant of stock options covering 6,500 shares of common stock, with an exercise price of $7.93 per share. These options are compensation, not an open-market purchase, and give her the right to buy shares in the future.
The options vest in 12 substantially equal monthly installments starting on July 11, 2026, as long as she maintains Continuous Service under the company’s 2021 Equity Incentive Plan. Any unvested portion will vest fully at the next annual stockholder meeting, and the options also fully vest upon her death, Disability, or a Change in Control. The options expire on June 10, 2036.